Cell biobank as a necessary infrastructure for the development and implementation of mesenchymal stem cell-based therapy in the treatment of anthracycline-induced cardiotoxicity. Literature review and own data

Abstract

Cardiovascular diseases, along with cancer, are the leading causes of death worldwide. Although modern pharmacological treatment of various cardiomyopathies can slow the development of myocardial dysfunction, they have limited effectiveness in patients with end-stage disease. Many researchers believe that heart transplantation is the only radical treatment in this case. However, the lack of donors and the high operation cost require careful selection of surgical candidates. With the introduction of molecular and cell biology into medical practice, today, stem cell therapy can become an alternative method of nonsurgical restoration of myocardial functions. The most studied and attractive is the use of mesenchymal stem cells (MSCs). MSCs differ from hematopoietic stem cells used as support for hematopoiesis in high-dose chemotherapy by the following features: pronounced trophic effect, immune tolerance, the ability to suppress alloreactivity and autoimmune disorders. An important stage in the implementation of cell therapy is the creation of a cell biobank of MSCs. In A.F.Tsyb Medical Radiological Research Center, this work has been carried out since1984. Asignificant number of experimental studies have been carried out, confirming the possibility of clinical implementation of this approach. A method for obtaining stable cultures of MSCs and cardiomyoblasts from bone marrow cells was developed and approvals were obtained. Experimental studies of cell therapy are also being conducted to overcome anthracycline-induced cardiotoxicity in cancer patients.This article is devoted to practical application of MSC-based therapy, in particular, in cancer patients with cardiotoxicity, as well as to the issues of creating a cell biobank for treatment with MSCs.

Cryostorage of Mesenchymal Stem Cells and Biomedical Cell-Based Products

“…Moreover, successful long-term storage facilitates the commercialization of therapeutic products [ 26 ]. Thus, the establishment of a cell-based material biobank will significantly empower research centers and manufacturers, as well as medical clinics as end users [ 27 ]. Biobanking typically implements technologies based on the use of low temperatures, with cryopreservation being the most widespread among them.…”

Estudo comparativo de proliferação e viabilidade celular pós criopreservação em células-tronco mesenquimais, obtidas do epitélio olfatório, tecido adiposo e âmnio de fetos caninos em terço final de gestação

“…Diante das possibilidades terapêuticas, vêm crecendo a necessidade de expansão in vitro em grande escala, com o intuito de garantir números de CTMs, adequadas para a aplicação clínica, o cultivo e principalmente o armazenamento, acaba por favorecer desde centros de pesquisa, fabricantes e principalmete o destinatário final, que seriam as clínicas veterinárias(SUELZU et al, 2020;GRIVTSOVA et al, 2020).Mediante a necessitade de expansão e de armazenamento celular por perídos prolongados, onde os aspectos estruturais e funcionais sejam promovidos, a quiescência celular obtida através da criopreservação é uma alternativa para a manutenção da diversidade biológica, visando o futuro das CTMs em terapias aplicacionais e em análises posteriores ao isolamento celular(EROL et al,2021).Baseados na utilização de baixas temperaturas, os biobancos, tem a criopreservação como técnica mais difundida e empregada ultimamente, mesmo apresentando influência de inúmeros fatores, tais como a composição e concentração de agentes crioprotetores, taxa de congelamento, duração do período de criopreservação, regime de temperatura bem como de descongelamento, dentre outros(JANG et al, 2017;DUAN et al, 2018).…”